How tumor-derived GABA disables tumor TLSs and drives anti-PD-1 resistance in cancer
Tumor-cell NY-ESO-1 Expression Predicts Poor Response to PD-1/PD-L1 Blockade in NSCLC
Background & rationale NY-ESO-1 is an immunogenic cancer-testis antigen and a therapeutic target for TCR-based strategies. Its value as a baseline biomarker for PD-1/PD-L1 blockade in NSCLC remains poorly defined. Because NY-ESO-1 is biologically relevant only when expressed by tumor epithelial cells, this study focused on CK7+/NY-ESO-1+ tumor cells. Study design Cohort 190 baseline FFPE […]
How ADORA2B drives metastasis in pleomorphic sarcoma — and why it’s a tractable target
How regorafenib plus avelumab reshapes the immune microenvironment of “cold” soft-tissue sarcomas — and why response stays elusive
Regorafenib plus avelumab in advanced neuroendocrine tumors — and the IDO1 biomarker that predicts resistance
Can an oncolytic virus turn “cold” sarcomas hot? Intratumoral JX-594 with avelumab raised CD8 T cells but not responses
Can blocking PRMT5 starve sarcomas of energy? Inhibiting the enzyme shuts down tumor glycolysis and growth
Why intravenous oncolytic virus JX-594 lit up immune biomarkers but not tumor responses in HR+ breast cancer
Why systemic oncolytic virus JX-594 stirred an immune signal but not clinical benefit in soft tissue sarcoma
Which biliary tract cancers benefit from regorafenib–avelumab — and which biomarkers matter?
